Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin degludec/liraglutide - Novo Nordisk

Drug Profile

Insulin degludec/liraglutide - Novo Nordisk

Alternative Names: IDegLira; Insulin degludec/Victoza; Liraglutide/insulin degludec; Liraglutide/NN 1250; Liraglutide/Tresiba; NN 1250/liraglutide; NN-9068; Tresiba/liraglutide; Victoza/insulin degludec; Xultophy

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Sep 2019 Launched for Type 2 diabetes mellitus in Japan (SC)
  • 13 Jul 2019 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in China (SC) (NCT03172494)
  • 01 Jun 2019 Registered for Type 2 diabetes mellitus in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top